Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Bevacizumab in Advanced Clear Cell Renal Carcinoma
NCT00455975Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Feb 2007
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in clear cell renal cell carcinoma (ccRCC), sponsored by SCRI Development Innovations. Started Feb 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00455975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455975.